naltrexone and Adenocarcinoma Of Kidney

naltrexone has been researched along with Adenocarcinoma Of Kidney in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berkson, BM; Calvo Riera, F	1
Conti, A; Kozlov, V; Laudon, M; Lissoni, P; Maestroni, G; Malugani, F; Malysheva, O	1
Bordin, V; Conti, A; Lissoni, P; Maestroni, G; Malugani, F; Tancini, G	1

Trials

2 trial(s) available for naltrexone and Adenocarcinoma Of Kidney

Article	Year
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system. Neuro endocrinology letters, 2002, Volume: 23, Issue:4 Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Digestive System Neoplasms; Female; Humans; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Male; Melatonin; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid Peptides; Pilot Projects	2002
A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro endocrinology letters, 2002, Volume: 23, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroimmunomodulation; Pilot Projects	2002

Article

Year

Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.

Neuro endocrinology letters, 2002, Volume: 23, Issue:4

Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Digestive System Neoplasms; Female; Humans; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Male; Melatonin; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid Peptides; Pilot Projects

2002

A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.

Neuro endocrinology letters, 2002, Volume: 23, Issue:3

Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroimmunomodulation; Pilot Projects

2002

Other Studies

1 other study(ies) available for naltrexone and Adenocarcinoma Of Kidney

Article	Year
The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol. Integrative cancer therapies, 2018, Volume: 17, Issue:3 Topics: Administration, Intravenous; Cancer Survivors; Carcinoma, Renal Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Integrative Oncology; Kidney Neoplasms; Male; Middle Aged; Naltrexone; Neoplasm Staging; Thioctic Acid; Time Factors	2018

Article

Year

The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol.

Integrative cancer therapies, 2018, Volume: 17, Issue:3

Topics: Administration, Intravenous; Cancer Survivors; Carcinoma, Renal Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Integrative Oncology; Kidney Neoplasms; Male; Middle Aged; Naltrexone; Neoplasm Staging; Thioctic Acid; Time Factors

2018